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Genetics Evaluation Guidelines for the Etiologic
Diagnosis of Congenital Hearing Loss
Genetic Evaluation of Congenital Hearing Loss Expert Panel
The advent of hearing screening in newborns in many states has led to an increase in the use of genetic testing
and related genetic services in the follow-up of infants with hearing loss. A significant proportion of those with
congenital hearing loss have genetic etiologies underlying their hearing loss. To ensure that those identified with
congenital hearing loss receive the genetic services appropriate to their conditions, the Maternal and Child Health
Bureau of the Health Resources and Services Administration funded the American College of Medical Genetics to
convene an expert panel to develop guidelines for the genetic evaluation of congential hearing loss. After a brief
overview of the current knowledge of hearing loss, newborn screening, and newborn hearing screening, we provide
an overview of genetic services and a guideline that describes how best to ensure that patients receive appropriate
genetic services. The significant contribution of genetic factors to these conditions combined with the rapid
evolution of knowledge about the genetics of these conditions overlaid with the inherently multidisciplinary nature
of genetic services provides an example of a condition for which a well-integrated multidisciplinary approach to care
is clearly needed. Genet Med 2002:4(3):162–171.
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BACKGROUND
Epidemiology
Hearing loss is relatively common in the human population.
Profoundcongenitalhearinglossisestimatedtooccurinabout1
in 1000 births; approximately 50% of cases are thought to be due
to environmental factors and the remainder to genetic causes1,2
(Fig.1).Examplesoftheformerincludeacoustictrauma,ototoxic
drugexposure(i.e.,aminoglycosides),andbacterialorviralinfec-
tions such as rubella or cytomegalovirus (CMV). Approximately
70% of congenital cases associated with genetic factors are classi-
fied as nonsyndromic (the deafness is not associated with other
clinical findings that define a recognized syndrome). In the re-
maining30%,oneofmorethan400formsofsyndromicdeafness
can be diagnosed because of associated clinical findings.1,3 The
auditory pathology varies widely among the many forms of syn-
dromic hearing loss and includes both conductive and sensori-
neural deficits that may be unilateral or bilateral, symmetrical or
asymmetrical, and progressive or stable.4
Theauditorypathologyofnonsyndromichearingimpairment
(NSHI) can also vary, but the deficits are most often sensorineu-
ral. Congenital NSHI is usually subdivided by mode of inheri-
tance:approximately77%ofNSHIisautosomalrecessive,22%is
autosomaldominant,and1%isX-linked.Theassociated“DeaF-
Ness” gene loci are designated DFNB (autosomal recessive),
DFNA (autosomal dominant), and DFN (X-linked). A variable
proportion of NSHI, perhaps less than 1%, is due to mitochon-
drialinheritance,2buttheproportionmaybemuchhigher(10%–
20%)insomepopulations5,6(Fig.1).Asageneralrule,individuals
with autosomal recessive NSHI have profound prelingual deaf-
ness, while dominant mutations lead to a more variable pheno-
type.Morethan90%ofchildrenwithcongenitalprofoundauto-
somal recessive NSHI are born to parents with normal hearing,
while the remaining 10% or less are born to deaf parents.
Over the past 5 years, remarkable progress has been made
identifying new hearing impairment loci and cloning new
genes for deafness. To date, at least 77 loci for NSHI have been
mapped:40autosomaldominant,30autosomalrecessive,and
7X-linked.7AsofJuly2001,50auditorygeneshavebeeniden-
tifiedandsequencedincluding14forautosomaldominantdis-
orders, 9 for autosomal recessive, 2 for X-linked, 5 mitochon-
drial,andatleast31genesforsyndromichearingloss.Insome
cases,differentmutationsatthesamelocushavebeenfoundto
cause syndromic and nonsyndromic forms of deafness. Al-
though significant advances have been made, it is clear that
moregenesandmutationsawaitdiscovery.Informationabout
these genes and their protein products is revolutionizing our
knowledge of the molecular processes involved in hearing and
enhancing our understanding of how the alteration of these
processes can lead to hearing loss. This knowledge may lead to
mutation-specific therapies that can delay or prevent certain
forms of genetic deafness such as the avoidance of aminogly-
cosidetherapyinthosewithspecificmitochondrialmutations.
History of newborn screening programs
Newborn screening programs for heritable disorders began in
theearly1960s.8Theyhaveevolvedintothecurrentpublichealth
newborn screening systems that include screening for metabolic
diseases, hemoglobinopathies, endocrine disorders, cystic fibro-
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addedtothislistofdisordersamenabletonewbornscreening.Six
essential components have been fundamental to the success of
theseprograms:(1)screeninginthenewbornperiod;(2)prompt
follow-up and referral; (3) diagnostic evaluation of infants with
positive screening test results; (4) prompt planning and imple-
mentation of management strategies; (5) continuous program
evaluation to ensure valid testing procedures, assess efficiency of
follow-up and intervention, and evaluate benefits to the patient,
family, and society; and (6) education of professionals and con-
sumers about the benefits and procedures involved in newborn
screening systems. In well-coordinated programs these compo-
nents are integrated to achieve the fundamental goal of reduced
mortality, morbidity, and disability for the screened infant.
In recent years, the impact of new technology and knowl-
edgehascausedarapidexpansioninthenumberofconditions
forwhichnewbornscreeningcanbeconsidered.9Thesefactors
have led to considerable variation among states, with some
states screening in either mandated or pilot programs for as
few as three conditions and others for as many as 30 or
more.10,11 In terms of the frequency of positive tests and the
potential number of detectable causes, introduction of popu-
lation-based screening for hearing loss represents a vast in-
crease in the number of fundamentally different genetic and
environmentalconditionsforwhichnewbornscreeningisnow
performed. This is an important consideration that is not
widelyrecognized.Oneofthegoalsofthisreportistohighlight
some of the unique features of congenital hearing loss detect-
able through newborn hearing screening.
History of hearing screening programs
Since the mid-1960s, active multidisciplinary efforts have
been directed to achieving early detection, diagnosis, and in-
tervention for children who are deaf or hard of hearing.12
Whileindividualhospitalsbegantoscreennewbornsforhear-
inglossasearlyas1970,widespreadacceptanceofthispractice
was not achieved until the late 1990s, following the 1993 NIH
Consensus Development Conference on Early Identification
of Hearing Impairment in Infants and Young Children that
recommendedthatallnewborninfantsbescreenedforhearing
shortly after birth.13
Many factors have contributed to the recent adoption and
spread of newborn screening for hearing loss.14,15 After an ex-
haustive evaluation of the relevant data, multiple professional
societies, advocacy groups, and government agencies partici-
pating in the Joint Committee on Infant Hearing (JCIH)16 en-
dorsed universal newborn hearing screening as an essential
componentofearlydetectionandinterventionforinfantswith
hearing loss.17 Professional organizations adopting the JCIH
statement include:
● American Academy of Audiology
● American Academy of Pediatrics
● American Speech-Language-Hearing Association
● Council on the Education of the Deaf
● Directors of Speech and Hearing Programs in State and
Health Welfare Agencies
Technologicadvancesinthephysiologicevaluationofhear-
ing in newborn infants have resulted in more accurate objec-
tiveaudiologicdiagnosis,whichhasopenedthedoorforearlier
detection. The subsequent development of automated audio-
logic screening algorithms has made it possible to generate
immediate outcomes from screening that do not require pro-
fessional interpretation, thus facilitating the development of
cost-efficientlarge-scalescreeningprograms.Theuseofsensi-
tive new technologies for screening (e.g., evoked otoacoustic
emissionsorauditorybrainstemresponsetesting)hassubstan-
tially reduced the number of infants without hearing loss who
fail the screening test (false positives) while achieving a high
rateofdetectionforinfantswithahearingloss(truepositives),
asshownbyresearchfundedbytheNationalInstituteonDeaf-
ness and Other Communication Disorders.18
Yoshinaga-Itano et al.19 and Moeller et al.20 have presented
critically needed outcome data showing that early detection of
hearingloss,accompaniedbytheintroductionofintervention
strategies within the first few months of life, results in infants’
subsequent development of language skills that approach the
skills of their peers who do not have hearing loss.
As of July 2001, more than two thirds of all states have en-
actedlegislationestablishingearlyhearingdetectionandinter-
vention (EHDI) programs. Legislation is pending in most of
the remaining states. Some states have established voluntary
universal newborn hearing screening and intervention pro-
grams. The net impact is that 65% of all newborns are now
screened for hearing loss shortly after birth, resulting in iden-
tificationoftwotothreebabiesper1000birthswithpermanent
hearing loss (defined as 30 decibels or more in at least one
ear).21 Increased participation in screening and improved co-
ordination of the reporting of results of evaluations among
providers and the medical home should enhance the benefits
realized from newborn hearing screening.
Fig. 1 “Distribution of causes” for profound hearing loss in infancy. The etiology of
lesser degrees of hearing loss in the newborn period is not well understood.
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ment provided funding to states from the Health Resources
and Services Administration and the Centers for Disease Con-
trol and Prevention to support the infrastructure required for
developing successful systems. This legislation included
money for planning, development, implementation, and re-
finement of EHDI programs and for EHDI tracking and data
management systems. The establishment of a large number of
new programs provides an unparalleled opportunity to iden-
tify and collect relevant data on hearing-impaired infants who
aredetectedbytheseprograms.Analysisofthesedatawilloffer
the maximum possible insight into secular and geographic
variation in the etiology of hearing loss while also providing
insight into the efficacy of early intervention in improving the
communication skills acquired by hearing-impaired children.
GENETIC EVALUATION PROGRAM
Genetic services overview
The successful mapping of the human genome has created
anexplosionofclinicallyrelevantknowledgethatcontinuesto
expand as the functions of our 30,000 or more genes are iden-
tified. Geneticists can play a major role in the management of
infants with newly detected hearing loss by facilitating the es-
tablishment of an etiologic diagnosis. The recently established
statewide EHDI programs provide an unusual opportunity to
develop cost-effective programs for delivering genetic services
to this new client group. Because of the limited pool of profes-
sionals adequately trained to perform competent genetic eval-
uation and counseling for the families of deaf and hard-of-
hearing infants, geneticists should not become involved in the
evaluation of deaf and hard-of-hearing infants until the pres-
ence of a hearing loss has been confirmed. We strongly believe
that a clearly articulated goal of EHDI programs should be the
identification and inclusion of a competent clinical geneticist
in the health care team managing newborns and infants with
hearing loss.
In general, deafness differs from many other “complex” ge-
netic diseases in that the hearing loss usually results from ab-
normalitiesinsinglegenesorgenepairs.However,someforms
ofdeafnessarebeginningtoberecognizedinwhichthehearing
loss may result from the combined effects of genes at two or
more loci. While abnormalities in many different single genes
or gene pairs can cause deafness, a remarkable finding is that
defectsinasinglegene,calledGJB2,giverisetomorethanhalf
of the genetic cases of profound deafness in the United States.
The GJB2 gene codes for a gap junction protein of the beta
subunitclassnamedconnexin26thatisinvolvedincell-to-cell
diffusion and recycling of small molecules such as potassium.
DNA-based molecular genetic tests are being developed to ac-
curately detect this and many other forms of genetic deafness.
Unfortunately, the knowledge base about the complexity of
genetic test results is still incomplete. Thus professionals who
arefullyawareoftheimplicationsandlimitationsofthemeth-
ods,technology,andcompetenciesofthelaboratoryshouldbe
the ones to interpret the test results, especially since many test
results are straightforward, but others are not. The ability to
understand and responsibly convey uncertainty is an inherent
partofthetrainingandpracticeofclinicalgeneticists,andonly
if an adequate system for the interpretation of genetic test re-
sults is available can their routine use for the evaluation of
children with deafness be recommended. Infants and children
with lesser degrees of hearing loss also need evaluation by a
clinical dysmorphologist because little is known about the
causes of deafness in this group of infants and children, and
some, perhaps many, may have subtle clinical abnormalities
that would allow diagnosis of a specific form of syndromic
deafness.
At the current time, interpretation of genetic testing results
ranges from the less complex to the highly complex. The time
between development of a new genetic test and its application
for medical diagnosis can be quite short. As knowledge accu-
mulates about the range of normal and pathologic variation,
and new test procedures are developed, the responsible inter-
pretation of genetic test results may become increasingly diffi-
cult. Complexity occurs because the most common and easily
understood genetic variations are found first and the less fre-
quent,morecomplexvariationsareonlyidentifiedwhenmore
people from a greater variety of ethnic backgrounds are evalu-
ated. In many cases, a genetic variant or a so-called “private
mutation” may be confined to a single family, and the strict
evidencethatitisofetiologicsignificancemaybelimitedtoits
cosegregation with a disease in that family and the fact that
different mutations involving the same gene cause the disease
in other families. For example, more than 45 different muta-
tions in the gene GJB2 can cause autosomal recessive NSHI,
butmostindividualsofNorthernEuropeanheritagewithGJB2
deafnesscarryatleastonecommonmutation,the35delG(de-
letion of a guanine nucleotide at position 35 from the start of
the initiation codon).22 In cases in which the spectrum of mu-
tations for any one gene may include common and rare vari-
ants, the usual requirements for establishing the clinical sensi-
tivity and specificity for every possible mutation must be
relaxed if the benefits of our investment in human genetics
research are to be realized by the general public. The potential
forvariationinthehumangenomeissovastthatthediscovery
of new mutations in disease-associated genes will be a never-
endingprocess.Obviously,theclinicaluseofmutationscreen-
ing for diagnostic purposes cannot be delayed until every mu-
tation has been discovered.
Over time, the interpretation of test results showing well-
understood variations becomes the standard. However, given
thealmostunlimitedcapacityforDNAtovaryamongindivid-
uals, it is reasonable to expect that complex interpretive issues
will always arise for other less common DNA changes. There-
fore, genetic counseling can also range from the communica-
tion of basic, well-established facts to the complex interpreta-
tion of imperfect knowledge that requires special skills in the
characterization and transmission of uncertainty. In some
families,complexstatisticalanalysisbasedonavailableclinical
and pedigree data may be required to provide the most accu-
rate characterization of genetic risks. Finally, genetic testing
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may impact recurrence chances addressed in counseling.
Hence, the provision of comprehensive genetic services is
commonly a multidisciplinary effort involving professionals
withspecialcompetenceinclinicalevaluation,laboratorytest-
ing, statistical analysis, and counseling.
It is not surprising that the issues that arise in providing
competent evaluation and counseling of the families of deaf
individualsrangefromrelativelystraightforwardtraitstosome
of the most complex problems and pedigrees encountered in
human genetics. Reducing the incidence and/or morbidity as-
sociated with hearing loss requires:
● Improved recognition of the importance of genetic fac-
tors in the etiology of deafness. Specific examples include
obstetricians’awarenessoftheimportanceofafamilyhis-
toryofhearinglossasapotentialriskfactorforaminogly-
cosideototoxicityintheneonatalintensivecareunitpop-
ulation and communicating this information to
neonatologists.
● Recognition that not all forms of hearing loss are ex-
pressed at birth and that surveillance, including the pos-
sibleuseofmolecularteststoidentifyhigh-riskcaseswho
would benefit from continued monitoring of their hear-
ing, is appropriate.
● Early identification of patients with certain forms of syn-
dromic deafness which can dramatically alter the risk of
serious complications for the affected infant and other
familymembers.Timelydiagnosisofsomegeneticcondi-
tions such as biotinidase deficiency and aminoglycoside
sensitivity can actually lead to prevention of hearing loss.
Definition of the condition
The definition of hearing loss used in this statement and in
screening programs is consistent with that of the Joint Com-
mittee on Infant Hearing Year 2000 Position Statement and
Guidelines.16 This loss is permanent and is bilateral or unilat-
eral,sensoryorconductive,andaverages30decibelsormorein
the frequency region important for speech recognition.
Evaluation
Appropriatemanagementofallpersonsidentifiedwithcon-
genital hearing loss, as defined above, requires a comprehen-
sive genetic evaluation. As noted previously, certain core per-
sonnel are required for the initial genetic evaluation and
counseling. Depending on the clinical findings, other special-
istsmayberequiredforacomprehensiveevaluation.Coreper-
sonnel include individuals with expertise in (1) the genetics of
hearing loss, (2) dysmorphology, (3) audiology, (4) otolaryn-
gology, (5) genetic counseling, and (6) communicating with
parentswhomaythemselvesbedeaf,includinguseofqualified
interpreting services.
Basedontheoutcomeoftheevaluation,variousothertypes
of professional expertise may also be needed, especially with
syndromal hearing loss (e.g., ophthalmology, cardiology, ne-
phrology, neurology, etc.).
The evaluation should include, at a minimum, a family his-
tory targeted at key genetic and phenotypic features of the
manyformsofsyndromicandnonsyndromichearingloss,and
a similarly targeted patient history and physical examination
(see Appendix 1 for details). The purpose of the genetic evalu-
ation is to establish an etiologic diagnosis.
The family history should specifically address:
1. Pedigree (three to four generations) with attention to
consanguinity, paternity, and hearing status of the par-
ents and siblings.
2. Ethnicity and country of origin.
3. Inheritance pattern of hearing loss (AD, AR, X-linked,
mitochondrial).
4. Audiometric characteristics in any deaf and hearing-im-
paired family members (age of onset, progression, con-
ductive hearing loss, nonsyndromic hearing loss, audi-
toryneuropathy).(Anattemptshouldbemadetocollect
and review previous records.)
5. Evidence of vestibular dysfunction.
6. Syndromic versus nonsyndromic features.
Toestablishwhetherthelossmayresultfromaspecificsyn-
drome, the practitioner should evaluate for, or inquire about,
the following conditions in the patient and/or relatives:
1. Visualanomalies,includingheterochromiairides,retini-
tis pigmentosa, myopia, retinal detachment, and early
cataracts.
2. Facial/cervical dysmorphology, including synophrys,
dystopia canthorum, preauricular pits, aural atresia,
branchial cysts, cleft palate, and dental anomalies.
3. Endocrine abnormalities such as thyromegaly and
diabetes.
4. Cardiac signs or symptoms, including syncope, sudden
death, arrhythmia, prolonged QT interval, fainting
spells, and congenital heart defect.
5. Renal abnormalities, including hematuria, proteinuria,
and structural defects.
6. Integumentarychangessuchasprematuregraying,whitefore-
lock,abnormalpigmentation,ordryskin/keratoderma.
The patient history should include specific risk factors such
as:
1. Intrauterineinfections(e.g.,toxoplasmosis,otheragents,
rubella, CMV, herpes simplex [TORCH]).
2. Meningitis.
3. Extracorporeal membrane oxygenation (ECMO).
4. History of hypoxia.
5. Prenatal alcohol exposure.
6. Exposure to ototoxic drugs.
The physical examination should include:
1. Otologic examination.
2. Airway examination.
3. Documentation of dysmorphisms.
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lar function in older patients.
After obtaining a family history, patient history, and physi-
cal examination, it may be possible to ascribe an etiology for
the hearing loss. For example, based on the family history and
physical examination, a diagnosis of branchio-oto-renal
(BOR) syndrome may be made. However, in about 30% of
patients, no obvious etiology will be apparent. It is important
to emphasize that a genetic cause is not excluded by such an
evaluation because patients with recessive NSHI can present
withoutafamilyhistoryofhearingloss(i.e.,asasimplexcase).
Animportantgoalofgeneticevaluationistoattempttodistin-
guish these isolated or simplex cases in which there may be a
25%chanceofdeafnessinsubsequentoffspringfromsporadic
cases caused by environmental factors with a low chance of
recurrence in families with no history of hearing loss.
Triage/testing and triage paradigm
Thegoaloftriage/testingistoestablishanetiologicbasisfor
hearing loss in the most efficient manner possible. Based on
results of the genetic evaluation, the following should be
considered:
1. If a form of syndromic deafness is suspected:
● Gene-specific mutation screening can be obtained in
many cases and more tests will undoubtedly become
available.
2. IfnonsyndromicdeafnessissuspectedANDthepatientis
a simplex case:
● CMV testing should be performed. A negative test for
CMV antibodies in early infancy may exclude CMV-re-
lated hearing loss. A positive result must be interpreted
with caution.
● GJB2 (connexin 26) mutation screening should be ob-
tainedbysequenceanalysis.Anegativetestresultdoesnot
exclude a genetic etiology; a positive test result may make
it possible to avoid other expensive and potentially inva-
sive tests.
3. IfnonsyndromicdeafnessissuspectedANDthepatientis
amultiplexcasewithotherhearing-impairedfirst-degree
relatives, proceed directly to connexin 26 testing.
4. IfnonsyndromicdeafnessissuspectedANDthepedigree
suggests dominant inheritance, connexin-related deaf-
ness is not excluded and gene-specific mutation screen-
ingforotherlocimaybeavailableonaresearchorclinical
investigation basis and will no doubt become increas-
ingly more available.
5. IfnonsyndromicdeafnessissuspectedANDthepedigree
suggests mitochondrial DNA inheritance:
● Testing for the A1555G mutation (associated with amin-
oglycoside-induced hearing loss) and the A7445G muta-
tion, both of which are associated with some rare familial
cases of hearing loss, may be appropriate after common
GJB2 mutations are excluded.
6. IfnonsyndromicdeafnessissuspectedANDbothparents
are deaf:
● Connexin-related deafness will be strongly suspected.
(Because mutations in GJB2 are the most common cause
of deafness in the United States, the vast majority of mar-
riages between deaf individuals who produce deaf off-
spring are between individuals with GJB2 mutations.)
● After triage/testing, it will be possible to ascribe a genetic
etiologytothehearinglossinmanypersons.Forexample,
a child may be diagnosed with GJB2-related deafness. If
twoclearlypathologicallelesarefound,wethenknowthe
cause of that child’s deafness with virtual certainty and
can accurately predict the chance of recurrence in a sub-
sequent child.
● Alternatively,mutationscreeningmaybenegative.Aneg-
ative mutation screen must NOT be taken to mean that
thedeafnessisNOTgenetic.Thisdistinctionissubtlebut
important, and currently is not adequately conveyed to
parentsofdeafchildrenwhoundergogenetictesting.23In
patients with an unremarkable family history of deafness
and a negative test result for connexin 26, the probability
that the deafness is genetic can be given. The probability
will vary based on the number of hearing siblings. The
proportional distribution of the different mutations in
the connexin 26 locus also varies in different ethnic
groups.22
Counseling and education
The purpose of genetic counseling is to ensure that the par-
ents/patientsunderstandthefindingsandlimitationsinherent
in any genetic evaluation. Successful delivery of genetic ser-
vicestoparents/familiesrequiresthatprofessionalsbesensitive
to cultural orientation and communication and psychosocial
needs.24 An individual’s approach to health may be based on
ethnicity,culturalhearingstatus,socioeconomicstatus,etc.At
least 10% of deaf infants will have deaf parents who may con-
sider themselves to be culturally Deaf. These infants represent
an important group identified by newborn hearing screening
programs. Service providers should ensure that arrangements
forprofessionalsignlanguageororalinterpretersaremadefor
deaf or hard-of-hearing parents. As with other cultures, mem-
bers are characterized by unique social and societal attributes
and a unique language (American Sign Language or ASL). It is
important in genetic counseling situations that family mem-
bers not be used as interpreters, since well-meaning family
membersmayfilterinformationandhavetheirownemotional
stake in the information being shared.
Optimally, counseling for deafness includes both pretest
and posttest sessions. A pretest session focuses on factual in-
formation, including an explanation of the different causes of
deafness, the types of genetic deafness that might play a role in
a specific family, modes of inheritance, and genetic testing op-
tions,includingtheirrisks,benefits,andlimitations.Aposttest
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the pretest session and an assessment of the psychosocial im-
pactthattheresultsmayhaveontheparents,child,andfamily.
It also is important to obtain feedback from families after pro-
viding genetic testing to assess their understanding of the im-
pact of these data.
Some deaf individuals have expressed reluctance to partici-
pate in genetic counseling for fear that they will be told not to
havechildren.25However,someofthesecouplesmaywelcome
the birth of a deaf child.25 Information and services should be
providedinafashionthatissensitivetodifferentreproductive
preferences or cultural differences. For example, during ge-
netic counseling, word choice can convey cultural bias. Use of
the words “chance” instead of “risk” for having a deaf or hear-
ing child and “deaf or hearing” instead of “affected or unaf-
fected” can help in removing cultural bias.24 Other terms such
as “handicapped,”“ pathology,”“ impairment,” may be offen-
siveorinappropriatetodeafandhard-of-hearingadultsandto
hearing parents as well.
Receptivity of parents to etiologic information may be pro-
foundlyinfluencedbytheiremotionalreactiontothediagnosis
of hearing loss in their child. Hearing parents may experience
grief and confusion regarding this unexpected diagnosis and
may feel a sense of urgency about where to turn for informa-
tion and decisions about communication and treatment op-
tions. It is important for professionals to know about appro-
priate referral networks specific to hearing loss for emotional
and decision-making support as referral of parents to support
services such as parent groups or psychosocial counseling is
appropriate in many situations. (See Appendix 2, Educational
and Informational Resources. Note that many resources are
available and this list is not meant to be exclusionary or
biased.)
It is important to empower parents by providing informa-
tion and support in order to help them avoid overdependence
on professionals and to involve them in decisions regarding
habilitation, etc. Parents may be more receptive to etiologic
information after their psychosocial needs have been met. In
addition to ensuring that medical needs are met, etiologic in-
formation can be extremely helpful in relieving guilt that par-
ents may feel about having a child with hearing loss (e.g., a
mother who may blame herself for the hearing loss due to an
unrelated event during her pregnancy) and can allay worry
about other complications that may appear in their child.
Attitudes of hearing parents and deaf and hard-of-hearing
peopletowardgenetictestingfordeafnessarealsoimportantto
consider, although such attitudes may not be predictive of be-
havior. Several studies of attitudes have been completed23,26,27
and demonstrate a variety of opinions about the appropriate
use of genetic technologies. While some deaf and hearing peo-
ple had a positive attitude toward genetic technology, many
were opposed to the use of genetic testing during prenatal di-
agnosisforthepurposeofpregnancyterminationbasedonthe
hearingstatusofthefetus.Thesesurveyspointouttheneedfor
furtherstudiestodeterminetheutilizationpatternsofprenatal
diagnosis for hearing loss and the need for all stakeholders to
engage in a discussion regarding the appropriate use of such
techniques.
Given the heightened public awareness of genetics, many
people have the incorrect belief that their DNA defines them.
Genetic information has even been called an individual’s “fu-
ture diary.”28 It is hardly surprising that one’s self-perception
canbealteredbylearningthatonehasageneticconditionoris
acarrierforageneticmutation.29Furthermore,auniquechar-
acteristic of genetic tests and information that separates them
from other medical information is that they reveal facts about
the entire family. Whereas most medical information applies
only to the individual seeking treatment, genetic information
has implications for anyone who shares or may share genes
with the person being tested. Obvious implications arise re-
garding genetic privacy for relatives of the patient. Do these
persons have a right to this information, even against the
wishes of the person who was tested? Conventional medical
ethics says no, as test results are privileged information to be
shared only with the expressed consent of the patient or the
patient’sparents.30,31However,someethicistshavearguedthat
all biologically related individuals have some claim to this in-
formation. As genetic testing becomes more common, the
scope of this problem will grow and will need to be addressed.
To date, neither the courts nor the legislative bodies have pro-
vided a definitive standard of practice on this issue.
Issues of genetic discrimination may also arise. While there
is much legislation to protect against it, insurance discrimina-
tion and even loss of insurance are a common concern for
people undergoing genetic testing.
Habilitation
Various treatment/habilitation options (e.g., otologic, au-
diologic,linguistic,andophthalmologic)areavailableandmay
be considered. Parents should be made aware of the available
options as part of the counseling process.
Follow-up
The purpose of follow-up is to ensure that the continued
health and hearing/aural needs of the patient and family are
being met. Follow-up should specifically include:
● Repeating the genetic evaluation, particularly if a specific
diagnosis was not made initially or if test results or addi-
tional molecular tests have become available.
● Repeating the audiometric evaluation.
● Evaluation of progressive loss. (An imaging study should
be obtained. The finding of Mondini dysplasia or dilated
vestibular aqueduct should prompt mutation screening
of SLC26A4 for Pendred syndrome/DFNB4.)
● Repeating the otolaryngologic examination.
● Other requests for subspecialty-directed examinations
based on the particular patient’s needs and associated
clinical findings. For example, patients at risk for neuro-
fibromatosis type 2 or suspected of having Stickler syn-
drome or Usher syndrome may require ophthalmologic
evaluation. Families with history of syncope or sudden
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evidence of renal disease may require a nephrology eval-
uation to exclude Alport syndrome or BOR syndrome.
BENEFITS
Anumberofbenefitscanresultfromensuringanappropri-
ate genetic evaluation as described in these guidelines. It is
possible to avoid unnecessary, costly clinical tests such as elec-
troretinograms, temporal bone imaging, and electrocardio-
grams. Determining or defining the cause of the hearing loss
providesanetiologicdiagnosisthatcandispelmisinformation
and offer emotional support by allaying parental guilt. Etio-
logic diagnosis also provides the basis for determining the
chancefordeafnessandrecurrenceofdeafnesswithinfamilies.
(For example, a person with autosomal recessive GJB2-related
deafnessandhis/herhearingspousehavea50%chanceofhav-
ing child with hearing loss if the hearing spouse also carries a
recessive GJB2 deaf-causing allele. Alternatively, if the hearing
spouse carries two normal GJB2 alleles, the chance of having a
deafchildislessthan10%andvarieswiththenumberofhear-
ing siblings.) Knowledge of etiology allows one to anticipate
potential/associated health problems and to offer appropriate
referral for therapeutic options (e.g., monitoring for myopia
andearlyretinaldetachmentinSticklersyndrome;obtaininga
renal examination to identify kidney complications in BOR)
and medical interventions such as amplification implants.
An individualized/personalized health maintenance strat-
egymaybeimplemented.Forexample,vitaminAtherapymay
be beneficial to persons with Usher syndrome in slowing reti-
nal degeneration, and treatment of children with Jervell and
Lange-Nielsensyndromecanminimizecardiaccomplications.
Diagnosis of biotinidase deficiency in children identified in
newborn screening programs enables biotin treatment to
avoid hearing loss. In persons carrying the mitochondrial mu-
tation, mtDNA A1555G, avoidance of aminoglycoside antibi-
otics reduces the risk of developing hearing loss.
RESEARCH NEEDS/ANTICIPATING CHANGES
The evaluation of scientific and medical literature on which
these recommendations are based also revealed a number of
areas in which data are deficient and research is needed. Simi-
larly, the history and speed of genetic test development allows
us to anticipate changes likely to be evident in the near future.
Expandingknowledgeofhumangeneticorinfectiouscausesof
later-onset congenital hearing loss offers the potential for the
addition of more genetic tests into newborn hearing screening
programs. Rapidly evolving new technologies will likely allow
the addition of microarrays and other kinds of high-through-
put testing to supplement the early detection of hearing loss
using available resources (e.g., newborn screening residual
driedbloodspots)andtestingforabroadspectrumofdeafness
and hearing loss–causing genes.
Asindividualswithgeneticcausesofdeafnessareidentified,
the opportunity to determine genotype/phenotype correla-
tions will emerge. Simultaneously, with the identification of
familieswithinheritedtypesofhearingloss,theopportunityto
understand better the variability in the expression of the mu-
tations will be possible. Knowledge of the biological pathways
in which the gene products are involved will likely allow for a
better understanding of this variable expressivity. The devel-
opmentandevaluationofgene-specifictherapy(e.g.,costben-
efit of vitamin A, antiusherin antibiotics, or medication to re-
duceretinitispigmentosasequelae)willbepossible.Therewill
also be opportunities to develop and test new clinical tools
such as a simple tool for vestibular assessments of infants.
Thecontinuedintegrationofgeneticsintopublichealthwill
require that there be a broader understanding and apprecia-
tionofindividualandpopulationvariability.Thegeneticdeaf-
ness load is population/ethnic-specific with most data derived
from populations of Northern European extraction. Data ap-
plicabletoabroadrangeofethnicgroupsisrequiredtoensure
comparableclinicalsensitivityofmutationdetectioninalleth-
nic groups. It will also be necessary to develop and implement
consistent data management tools among various newborn
screeningprograms.Withtherapidintroductionofmolecular
methods into both hearing and classical newborn screening
programs, such tools will allow for uniform communication,
evaluation, and comparison of screening programs and strat-
egies to identify the most successful screening and follow-up
programs.
LIMITATIONS
A number of limitations exist with regard to the delivery of
the genetic services related to congenital hearing impairment.
An underlying problem that these guidelines seek to minimize
is the limited education, exposure, and experience with genet-
ics and genetic services of most in the health care system. Few
people are trained in delineating the etiology of these disor-
ders,therebycomplicatingimplementationofacompletepro-
gram in all areas of the country. Model systems must be devel-
oped and disseminated. Because of the high volume of testing
expectedinthisarea,itisimportantthatattentionandsupport
be given to the development of links among the many provid-
ers involved in the identification, diagnosis, and follow-up of
congenital hearing loss. Further exacerbating the limited
knowledge of genetics by many providers is the rapidly devel-
opingand,therefore,unstablebodyofknowledgeofthegeno-
type/phenotype correlations and the expanding technologies
used to detect the mutations associated with these conditions.
This rapid development of the knowledge base and new tests
also requires us to consider issues related to recontacting pa-
tients and ensuring that patients maintain links to providers.
Many genetic tests for hereditary hearing loss remain quite
variableinmethodsandmutationstested.Clinicalsensitivityis
often less than 100%, and patients must appreciate that not
identifying one of the known mutations does not necessarily
mean that one is not present. The genetics provider commu-
nitymustworktowardstandardizingtesting.Inaddition,only
a limited number of laboratories offer testing related to the
Expert panel
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development of hearing loss are also quite limited for many of
its causes.
To ensure the maximal data acquisition to improve and fine-
tune our understanding of clinical validity and utility of these
tests, data collection that is currently ad hoc should be well coor-
dinated and centralized to maximize the value of its content.
GENERAL INFORMATION AND EDUCATION RESOURCES
Numerousresourcesareavailabletoprofessionalsandtothe
public. See Appendix 2, Educational and Informational Re-
sources, for a partial list that includes those that offer compre-
hensive lists of available resources.
Approved by the Board of Directors of the American College of
Medical Genetics, October 2001.
  AMERICAN COLLEGE OF MEDICAL GENETICS, 2002.
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Appendix 1
Important Evaluation Considerations for Genetic Service Providers:
Checklist items
A.Familyhistorycomponentsfordeterminingetiologyofcon-
genital hearing loss
Ethnicity
Consanguinity
Family history of hearing loss: If yes, determine type, sever-
ity, age of onset, stability versus progression, presence or
absence of vestibular symptoms, other associated findings,
availability of records
Targetedfamilyhistorybysystems(threetofourgenerations):
Integumentary: white forelock (may repigment with time);
other unusual hair color, texture, or pattern (e.g., sparse,
unusually curly); premature gray hair; acquired or congeni-
tal, white or brown spots (macules) or lentigines; abnormal
eyebrows, lashes, or nails; dry skin/keratoderma
HEENT: abnormal ear shape, size, ear canals, preauricu-
lar skin tag or sinus; ocular malformation, iris hetero-
chromia,congenitalglaucoma,cataract,moderate-severe
myopia, retinal detachment, optic atrophy, or retinitis
pigmentosa; cleft lip and/or palate; micrognathia, other
craniofacial or ocular malformation or abnormality
Neck: sinus, cartilage remnant, cyst, mass, goiter
Cardiovascular: congenital malformation; irregular heart
beat; arrhythmia; fainting spells; history of sudden infant
death syndrome in a close family member
Gastrointestinal: Hirschsprung disease; severe chronic
constipation beginning in early childhood
Skeletal:unusuallytallorshortstature,“marfanoid”hab-
itus, scoliosis, joint laxity, any limb anomaly
Neurologic: child or fetus with neural tube defect; any
progressive vision loss, ptosis, nystagmus; seizures, espe-
cially associated with sudden death; muscle weakness,
myopathy, muscular dystrophy, myotonia; chronic or
progressive ataxia; other progressive or debilitating neu-
rologic disorder
Endocrine: diabetes mellitus, diabetes insipidus; goiter,
other thyroid disease; hypogonadism, infertility
B. Congenital hearing loss: prenatal and perinatal history
Prenatal history
Maternal fever (document magnitude and duration)
Maternal rash (document type, location, duration)
Maternal known exposure
Maternal TORCH status
Viral cultures or polymerase chain reaction studies at birth
Other evidence of prenatal infection
Prenatalexposuretopotentiallyototoxicdrugsincluding
alcohol and cocaine
Hydrops fetalis
Perinatal history
Intrauterine growth restriction
Low birth weight appropriate for gestational age (1500 g)
Low Apgar score(s)
One-minute Apgar 0–4
Five-minute Apgar 0–6
Neonatal intensive care unit admission
Neonatal meningitis
Mechanical hyperventilation (with alkalosis)
Persistent hypotonia (at least 2 hours)
Neonatal seizures
Hyperbilirubinemia requiring exchange transfusion (or
meeting criteria for exchange)
Persistentpulmonaryhypertension/fetalcirculation;ECMO
Treatment with aminoglycoside antibiotics
Failed newborn screening for hypothyroidism
Documentation of prior evaluations
TORCH titers, especially IgM for rubella and CMV
Electrocardiogram, especially prolonged monitoring
CMV testing by culture or DNA in the neonatal period
Computed tomography or magnetic resonance imaging of
the temporal bone: Mondini defect; dilated vestibular
aqueduct
Mutation analysis for a known deafness gene
Ophthalmology consult
Appendix 2
Educational and Informational Resources
The majority of resources listed below are comprehensive
compilationsofresourcesdevelopedbynationalorganizations
andfederalagencies.AdditionalimportantInternet-accessible
resources of research and practice databases are included.
● Communicating Informed Consent to Individuals Who
Are Deaf and Hard-of-Hearing. National Institute on
Deafness and Other Communication Disorders
(NIDCD)
● NIH Publication 00-4689, September 1999
● DirectoryofInformationResourcesforHumanCommu-
nication Disorders. National Institute on Deafness and
Other Communication Disorders (NIDCD) Information
Clearinghouse,1CommunicationAvenue,Bethesda,MD
20892
● Early Identification of Hearing Loss: Implementing Uni-
versal Newborn Screening Programs. National Maternal
and Child Health Clearinghouse, 2070 Chain Bridge
Road, Suite 450, Vienna, VA 22182-2536
Web sites for the public
● Early Hearing Detection and Intervention Program
(EHDI): www.cdc.gov/ncbddd/ehdi
Expert panel
170 Genetics IN Medicine● National Center for Hearing Assessment and Manage-
ment (NCHAM): www.infanthearing.org
Web site for hereditary hearing loss researchers
● Hereditary hearing loss: www.uis.ac.be/dnalab/hhh
Web sites for professionals
● GeneClinics: www.geneclinics.org
● National Newborn Screening Genetics Resource Center:
Genes-R-Us.UTHSCSA.edu
Thisguidelineisdesignedprimarilyasaneducationalresourceformedicalgeneticistsandotherhealthcareproviderstohelpthem
providequalitymedicalgeneticservices.Adherencetothisguidelinedoesnotnecessarilyensureasuccessfulmedicaloutcome.This
guideline should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are
reasonablydirectedtoobtainingthesameresults.Indeterminingtheproprietyofanyspecificprocedureortest,thegeneticistshould
applyhisorherownprofessionaljudgmenttothespecificclinicalcircumstancespresentedbytheindividualpatientorspecimen.It
may be prudent, however, to document in the patient’s record the rationale for any significant deviation from this guideline.
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